Could a vaccine stop lung cancer before it starts?

NCT ID NCT07169617

First seen Nov 01, 2025 · Last updated Apr 25, 2026 · Updated 34 times

Summary

This study tests a vaccine called SurVaxM in 80 current or former smokers at high risk for lung cancer. The vaccine trains the immune system to attack cells that produce a protein called survivin, which is common in early lung cancers. If successful, this approach could help prevent lung cancer from developing in people with a heavy smoking history.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Northwestern University

    Chicago, Illinois, 60611, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Rocky Mountain Regional VA Medical Center

    Aurora, Colorado, 80045, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Roswell Park Cancer Institute

    Buffalo, New York, 14263, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Tennessee - Knoxville

    Knoxville, Tennessee, 37920, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.